非小细胞肺癌的标靶治疗幻灯片1.pptVIP

Targeted Therapy in Non-Small-Cell Lung Cancer;主要癌症每十萬人口死亡數;Fry WA, et al. Cancer. 1996;77:1953.;NSCLC Treatment;The “First Generation” Agents;The “2nd Generation” Agents;The “3rd Generation” Agents;The “4th Generation” Agents;Target Validation;;Epidermal Growth Factor Receptor Inhibition (EGFRI) ;EGFR expression in human tumours ;Inhibition of the EGFR signaling pathway;Tyrosine kinase inhibitors (TKIs) ;;IDEAL 1 2: design schema;IDEAL 1: tumour response rate;IDEAL 1: disease control rate;IDEAL 1: tumour response rate ;IDEAL 2: tumour response rate;IDEAL 2: disease control rate;Time to improvement (days);IDEAL2:Time to Symptom Improvement;Prognostic Factors Associated with an Objective Response;IDEAL 1: drug-related toxicities by dose;IDEAL 2: drug-related toxicities by dose;Pre-treatment;Accelerated approval regulations;Acute Interstitial Pneumonitis;J Chin Med Assoc ? April 2005 ? Vol 68 ? No 4;Iressa-related AIP in Taiwan ;Iressa combined with chemotherapy;End points Primary: Survival Secondary: TTF ORR QoL, symptoms Safety Exploratory: Tumour biomarker analysis (eg EGFR);;Survival;Survival;; Marketing Authorization Application Withdrawn in Europe ;Erlotinib in Previously Treated Non-small-cell Lung Cancer, BR 21 ;;;Tarceva combined with Chemotherapy;Who correlated with EGFR-TKI response;EGFR Mutation;;;EGFR Mutation;健保局適應症;EGFR Monoclonal Antibody;;Cetuximab;Cetuximab;Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated pts with stage IV NSCLC. ;Phase II Trial of Cetuximab in Patients With PreviouslyTreated Non–Small-Cell Lung Cancer; Vascular Endothelial Growth Factor (VEGF) Monoclonal Antibody ;Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.;Tumors absorb nutrients and oxygen by simple diffusion up to a size of 1-2 mm. Their further growth requires the elaboration of a vascular supply.;Phase II Trial Comparing BevacizumabPlus Carboplatin and Paclitaxel With Carboplatin andPaclit